热门资讯> 正文
Evotec Biologics赢得人工智能驱动的单克隆抗体优化拨款
2026-01-08 15:01
- Evotec SE (EVO) (EVOTF) Thursday reported that its Seattle-based subsidiary, Just-Evotec Biologics, has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just-Evotec Biologics' molecular design suite of computational technologies, called "J.MD™".
- Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities.
- This grant extends the commitment of Just - Evotec Biologics, which began in 2014 and has since delivered multiple cGMP manufacturing campaigns for RSV, malaria, and HIV monoclonal antibodies, the company said.
More on Evotec SE
- Evotec: How Low A Company May Go While Still Being Attractive
- Evotec SE 2025 Q3 - Results - Earnings Call Presentation
- Evotec SE (EVO) Q3 2025 Earnings Call Transcript
- Evotec gets $5M milestone payment from Bristol Myers after FDA accepts new drug application
- Evotec SE reports Q3 results
推荐文章
财报大跌背后：微软正在进行一场昂贵但精准的“利润置换”
港股IPO持续火热！下周6股排队上市，“A+H”占比一半
港股周报 | “AI红包大战”厮杀！腾讯周内暴跌近10%、阿里重挫8%，南下资金出手560亿港元大举抄底
美股机会日报 | 止跌企稳！纳指期货盘前涨约0.5%，有分析称美股连遭重挫后或回升；亚马逊盘前大跌超8%
一周财经日历 | 事关降息！美国1月非农、CPI数据下周公布；恒指季检结果下周五揭晓
华尔街大多头漫谈黄金“黑天鹅”风险：马斯克实现太空采金，化身全球央行行长
亚马逊股价盘后大跌近10%，巨额资本支出引发担忧
2月6日外盘头条：比特币暴跌 亚马逊预计今年资本支出将达2000亿美元 交易员料美联储将比预期更早降息
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
